First Novozymes product approved
The approval of GlaxoSmithKline’s Eperzan – a challenger to Novo Nordisk Victoza – also marks the first time that a drug based on technology from Novozymes makes it to market.
by Stefan Singh Kailay
A long journey has finally come to an end with the approval of the newest GLP-1 analogue Eperzan (albiglutid) from British pharma giant GlaxoSmithKline.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novozymes: More challenging than we expected
For abonnenter
Analyst: Novozymes underestimates one thing
For abonnenter
Novozymes in collaboration with US biotech company
For abonnenter
